Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies
More effective therapies are emerging, with better toxicity profiles, and are being incorporated into modern treatment algorithms of chronic lymphocytic leukemia at various stages of the disease, including for patients harboring Del17p and/or aberrant TP53. Ibrutinib, an inhibitor of Bruton’s tyrosi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-03-01
|
| Series: | Hematology/Oncology and Stem Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1658387617300535 |